Restricted accessResearch articleFirst published online 2013-2
Detection of the Epidermal Growth Factor Receptor,Amphiregulin and Epiregulin in Formalin-Fixed Paraffin-Embedded Human Placenta Tissue by Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging
The study of the expression and the tissue distribution of the tyrosine kinase drug-target epidermal growth factor receptor (EGFR) is of interest in oncology as a marker of potential efficacy of treatment. It has been reported, however, that the response rates to anti-EGFR drugs are poorly linked to its expression. Clinical studies have also revealed a patient response correlation with the expression levels of two EGFR ligands; amphiregulin and epiregulin. Here, we report the development of a matrix-assisted laser desorption/ionisation mass spectrometry imaging methodology for the study of EGFR, epiregulin and amphiregulin distribution in formalin fixed paraffin embedded human placental tissue and a comparison to expression patterns obtained by immunohiostochemistry. Using on-tissue digests and imaging of specific peptides, the tissue distribution of these proteins has been obtained down to 30 μm spatial resolution.
HanahanD.WeinbergR.A., “Hallmarks of cancer: The next generation”, Cell144, 646 (2011). doi: 10.1016/j.cell.2011.02.013
5.
CiardielloF.TortoraG., “A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor”, Clin. Cancer Res.7, 2958 (2001).
6.
HartmannJ.T.HaapM.KopH.G.LippH.P., “Tyrosine kinase inhibitors—a review on pharmacology, metabolism and side effects”, Current Drug Metabolism5, 470 (2009). doi: 10.2174/138920009788897975
7.
MoroniM.VeroneseS.BenvenutiS.MarrapeseG.Sartore-BianchiA.Di NicolantonioF.GambacortaM.SienaS.BardelliA., “Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: A cohort study”, Lancet Oncology5, 279 (2005). doi: 10.1016/S1470-2045(05)70102-9
8.
EngelmanJ.A.JanneP.A., “Factors predicting response to EGFR tyrosine kinase inhibitors”, Semin. Resp. Crit. Care Med.26, 314 (2005). doi: 10.1055/s-2005-871990
9.
PersoneniN.HendliszA.GallezJ.GaldonM.G.LarsimontD.Van LaethemJ.L.NagyN.BaretteM.PaesmansM.CardosoF.BleibergH., “Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer”, Semin. Oncol.32(Suppl 9), S59 (2005). doi: 10.1053/j.seminoncol.2005.04.029
10.
LièvreA.BachetJ.B.Le CorreD.BoigeV.LandiB.EmileJ.F.CôtéJ.F.TomasicG.PennaC.DucreuxM.RougierP.Penault-LlorcaF.Laurent-PuigP., “KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer”, Cancer Res.66, 3992 (2006). doi: 10.1158/0008-5472.CAN-06-0191
11.
Sartore-BianchiA.MoroniM.VeroneseS.CarnaghiC.BajettaE.LuppiG.SobreroA.BaroneC.CascinuS.ColucciG.CortesiE.NichelattiM.GambacortaM.SienaS., “Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab”, J. Clin. Oncol.25, 3238–3245 (2007). doi: 10.1200/JCO.2007.11.5956
12.
AmadoR.G.WolfM.PeetersM.Van CutsemE.SienaS.FreemanD.J.JuanT.SikorskiR.SuggsS.RadinskyR.PattersonS.D.ChangD.D., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer”, J. Clin. Oncol.26, 1626 (2008). doi: 10.1200/JCO.2007.14.7116
13.
SienaS.Sartore-BianchiA.Di NicolantonioF.BalfourJ.BardelliA., “Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer”, J. Natl. Cancer Inst.101, 1308 (2009). doi: 10.1093/jnci/djp280
14.
ChenZ.Y.ZhongW.Z.ZhangX.C.SuJ.YangX.N.ChenZ.H.YangJ.J.ZhouQ.YanH.H.AnS.J.ChenH.J.JiangB.Y.MokT.S.WuY.L., “EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas”, Oncologist17, 978 (2012). doi: 10.1634/theoncologist.2011-0385
15.
BiancoR.TroianiT.TortoraG.CiardielloF., “Intrinsic and acquired resistance to EGFR inhibitors in Human cancer therapy”, Endocr-Relat. CancerSuppl. 1, S159 (2005).
16.
MorgilloF.BareschinoM.A.BiancoR.TortoraG.CiardielloF., “Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy”, Differentiation75, 788 (2007). doi: 10.1111/j.1432-0436.2007.00200.x
17.
RhoJ.K.ChoiY.J.LeeJ.K.RyooB.Y.NaI.I.YangS.H.LeeS.S.KimC.H.YooY.D.LeeJ.C., “The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors”, Mol. Cancer Res.10, 1736 (2009). doi: 10.1158/1541-7786.MCR-08-0504
18.
WheelerD.L.DunnE.F.HarariP.M., “Understanding resistance to EGFR inhibitors-impact on future treatment strategies”, Natl. Rev. Clin. Oncol.9, 493 (2010)7.
19.
BonannoL.JirilloA.FavarettoA., “Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors and new therapeutic perspectives in non small cell lung cancer”, Curr. Drug Targets12, 922 (2011). doi: 10.2174/138945011795528958
20.
SudaK.MizuuchiH.MaeharaY.MitsudomiT., “Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny”, Cancer Metast. Rev.31, 807 (2012). doi: 10.1007/s10555-012-9391-7
21.
TabaraK.KandaR.SonodaK.KuboT.MurakamiY.KawaharaA.AzumaK.AbeH.KageM.YoshinagaA.TahiraT.HayashiK.AraoT.NishioK.RosellR.KuwanoM.OnoM., “Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells”, PLoS One7, e41017 (2012). doi: 10.1371/journal.pone.0041017
22.
BaselgaJ., “Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?”, Natl. Clin. Pract. Oncol.2, 284 (2005). doi: 10.1371/journal.pone.0041017
23.
CunninghamD.HumbletY.SienaS.KhayatD.BleibergH.SantoroA.BetsD.MueserM.HarstrickA.VerslypeC.ChauI.CutsemV., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer”, New Engl. J. Med.351, 337 (2004). doi: 10.1056/NEJMoa033025
24.
HechtJ.R.PatnaikA.BerlinJ.VenookA.MalikI.TchekmedyianS.NavaleL.AmadoR.G.MeropolN.J., “Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer”, Cancer110, 980 (2007). doi: 10.1002/cncr.22915
25.
ChungK.Y.ShiaJ.KemenyN.E.ShahM.SchwartzG.K.TseA.HamiltonA.PanD.SchragD.SchwartzL.KlimstraD.S.FridmanD.KelsenD.P.SaltzL.B., “Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry”, J. Clin. Oncol.23, 1803 (2005). doi: 10.1200/JCO.2005.08.037
26.
MoroniM.VeroneseS.Sartore-BianchiA.ArtaleS.SienaS., “Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: A case report and review of the literature”, Target. Oncol.3, 127 (2008). doi: 10.1007/s11523-008-0073-x
27.
GustersonB.A.HunterK.D., “Should we be surprised at the paucity of response to EGFR inhibitors?”, Lancet Oncol.10, 522 (2009). doi: 10.1016/S1470-2045(09)70034-8
28.
AllegraC.J.JessupJ.M.SomerfieldM.R.HamiltonS.R.HammondE.H.HayesD.F.McAllisterP.K.MortonR.F.SchilskyR.L., “American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy”, J. Clin. Oncol.27, 2091 (2009). doi: 10.1200/JCO.2009.21.9170
29.
JhawerM.GoelS.WilsonA.J.MontagnaC.LingY.H.ByunD.S.NasserS.ArangoD.ShinJ.KlampferL.AugenlichtL.H.Perez-SolerR.MariadasonJ.M., “PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab”, Cancer Res.68, 1953–1961 (2008). doi: 10.1158/0008-5472.CAN-07-5659
30.
BonannoL.SchiavonM.NardoG.BertorelleR.BonaldiL.GalligioniA.IndraccoloS.PaselloG.ReaF.FavarettoA., “Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma”Anticancer Res.30, 5121 (2010).
31.
TolJ.DijkstraJ.R.KlompM.TeerenstraS.DommerholtM.Vink-BörgerM.E.van CleefP.H.van KriekenJ.H.PuntC.J.NagtegaalI.D., “Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab”, Eur. J. Cancer46, 1997 (2010). doi: 10.1016/j.ejca.2010.03.036
32.
LièvreA.BachetJ.-B.BoigeV.CayreA.Le CorreD.BucE.YchouM.BoucheO.LandiB.LouvetC.AndreT.BibeauF.DieboldM.-D.RougierP.DucreuxM.TomasicG.EmileJ.-F.Penault-LlorcaF.Laurent-PuigP., “KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab”, J. Clin. Oncol.26, 374 (2008). doi: 10.1200/JCO.2007.12.5906
33.
CappuzzoF.FinocchiaroG.RossiE.JänneP.A.CarnaghiC.CalandriC.BencardinoK.LigorioC.CiardielloF.PressianiT.DestroA.RoncalliM.CrinoL.FranklinW.A.SantoroA.Varella-GarciaM., “EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients”, Ann. Oncol.19, 717 (2008). doi: 10.1093/annonc/mdm492
34.
IchiharaS.ToyookaS.FujiwaraY.HottaK.ShigematsuH.TokumoM.SohJ.AsanoH.IchimuraK.AoeK.AoeM.KiuraK.ShimizuK.DateH.ShimizuN., “The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer”, Int. J. Cancer120, 1239 (2007). doi: 10.1002/ijc.22513
35.
CappuzzoF., “EGFR FISH versus mutation: Different tests, different end-points”, Lung Cancer60, 160 (2008). doi: 10.1016/j.lungcan.2008.02.008
36.
ItalianoA.FollanaP.CaroliF.X.BadettiJ.L.BenchimolD.GarnierG.GugenheimJ.HaudebourgJ.KeslairF.LesbatsG.LledoG.RousselJ.F.PedeutourF.FrançoisE., “Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number”, Ann. Surg. Oncol.15, 649 (2008). doi: 10.1245/s10434-007-9667-2
37.
Khambata-FordS.GarrettC.R.MeropolN.J.BasikM.HarbisonC.T.WuS.WongT.W.HuangX.TakimotoC.H.GodwinA.K.TanB.R.KrishnamurthiS.S.BurrisH.A.3rdPoplinE.A.HidalgoM.BaselgaJ.ClarkE.A.MauroD.J., “Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab”, J. Clin. Oncol.25, 3230–3237 (2007). doi: 10.1200/JCO.2006.10.5437
38.
YonesakaK.ZejnullahuK.LindemanN.HomesA.J.JackmanD.M.ZhaoF.RogersA.M.JohnsonB.E.JänneP.A., “Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers”, Clin. Cancer Res.14, 6963 (2008). doi: 10.1158/1078-0432.CCR-08-0957
39.
JacobsB.De RoockW.PiessevauxH.Van OirbeekR.BiesmansB.De SchutterJ.FieuwsS.VandesompeleJ.PeetersM.Van LaethemJ.L.HumbletY.Pénault-LlorcaF.De HertoghG.Laurent-PuigP.Van CutsemE.TejparS., “Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab”, J. Clin. Oncol.27, 5068 (2009). doi: 10.1200/JCO.2008.21.3744
40.
BakerJ.B.DuttaD.WatsonD.MaddalaT.MunnekeB.M.ShakS.RowinskyE.K.XuL.A.HarbisonC.T.ClarkE.A.MauroD.J.Khambata-FordS., “Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer”, Brit. J. Cancer104, 488–495 (2011). doi: 10.1038/sj.bjc.6606054
41.
ChangM.H.AhnH.K.LeeJ.JungC.K.ChoiY.L.ParkY.H.AhnJ.S.ParkK.AhnM.J., “Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors”, Cancer117, 143 (2011). doi: 10.1002/cncr.25560
42.
KuramochiH.NakajimaG.KanekoY.NakamuraA.InoueY.YamamotoM.HayashiK., “Amphiregulin and epiregulin mRNA expression in primary colorectal cancer and corresponding liver metastases”, BMC Cancer12, 88 (2012). doi: 10.1186/1471-2407-12-88
43.
ParkJ.H.HanS.W.OhD.Y.ImS.A.JeongS.Y.ParkK.J.KimT.Y.BangY.J.ParkJ.G., “Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer”, Cancer Chemoth. Pharm.68, 1045 (2011). doi: 10.1007/s00280-011-1586-z
44.
LemaireR.DesmonsA.TabetJ.C.DayR.SalzetM.FournierI., “Direct analysis and MALDI imaging of formalin-fixed, paraffin-embedded tissue sections”, J. Proteome Res.6, 1295 (2007). doi: 10.1021/pr060549i
45.
DjidjaM.-C.ClaudeE.SnellM.ScrivenP.FranceseS.CarolanV.A.ClenchM.R., “MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin fixed paraffin embedded pancreatic adenocarcinoma tissue sections”, J. Proteome Res.8, 4876 (2009). doi: 10.1021/pr900522m
46.
DjidjaM.-C.ClaudeE.SnellM.ScrivenP.CarolanV.A.ClenchM.R., “Novel molecular tumour classification using MALDI-mass spectrometry imaging of tissue micro array”, Anal. Bioanal. Chem.397, 587 (2010). doi: 10.1007/s00216-010-3554-6
47.
JiangJ.ParkerC.E.HoadleyK.A.PerouC.M.BoysenG.BorchersC.H., “Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis”, Proteom. Clin. Appl.1, 1651 (2007). doi: 10.1002/prca.200700009
48.
TaguchiF.SolomonB.GregorcV.RoderH.GrayR.KasaharaK.NishioM.BrahmerJ.SpreaficoA.LudoviniV.MassionP.P.DziadziuszkoR.SchillerJ.GrigorievaJ.TsypinM.HunsuckerS.W.CaprioliR.DuncanM.W.HirschF.R.BunnP.A.JrCarboneD.P., “Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study”, J. Natl. Cancer Inst.99, 11838 (2007). doi: 10.1093/jnci/djk195
49.
RoderH.TsypinM.GrigorievaJ., Monitoring Treatment of Colorectal Cancer Patients with Drugs Targeting EGFR Pathway Using Mass Spectrometry of Patient Samples, United States Patent No. US8,119,418 B2.
50.
HoekstraA.HerscheidJ.D., “The placenta as a substitute for cancerous models”, Med. Hypotheses17, 299 (1985). doi: 10.1016/0306-9877(85)90088-X
51.
MurrayM.J.LesseyB.A., “Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis”, Semin. Reprod. Endocr.17, 275 (1999). doi: 10.1055/s-2007-1016235
52.
FerrettiC.BruniL.Dangles-MarieV.PeckingA.P.BelletD., “Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts”, Hum. Reprod. Update13, 121 (2007). doi: 10.1093/humupd/dml048
53.
MühlhauserJ.CrescimannoC.KaufmannP.HöflerH.ZaccheoD.CastellucciM., “Differentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 oncogene product and EGFR”, J. Histochem. and Cytochem.41, 165 (1993). doi: 10.1177/41.2.8093455
54.
MaruoT.MatsuoH.OtaniT.MochizukiM., “Role of epidermal growth factor (EGF) and its receptor in the development of the human placenta”, Reprod. Fert. Develop.7, 1465 (1995). doi: 10.1071/RD9951465
55.
LysiakJ.J.JohnsonG.R.LalaP.K., “Localization of amphiregulin in the Human placenta and decidua throughout gestation: Role in trophoblast growth”, Placenta16, 359 (1995). doi: 10.1016/0143-4004(95)90093-4
56.
ToyodaH.KomurasakiT.UchidaD.MorimotoS., “Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family”, Biochem. J.326, 69 (1997).
57.
StauberJ.MacaLeeseL.FranckJ.ClaudeE.SnelM.KaletasB.K.WielI.M.V.D.WitztorskiM.FournierI.HeerenR., “On-tissue protein identification and imaging by MALDI-ion mobility mass spectrometry”, J. Am. Soc. Mass Spectrom.21, 338 (2010). doi: 10.1016/j.jasms.2009.09.016
58.
SchoberY.SchrammT.SpenglerB.RomppA., “Protein identification by accurate mass matrix-assisted laser desorption/ionization imaging of tryptic peptides”, Rapid Commun. Mass Spectrom.25, 2475 (2011). doi: 10.1002/rcm.5135
59.
AnagnostouV.K.WelshA.W.GiltnaneJ.M.SiddiquiS.LiceagaC.GustavsonM.SyrigosK.N.ReiterJ.L.RimmD.L., “Analytic variability in immunohistochemistry biomarker studies”, Cancer Epidem. Biomar.19, 982 (2010). doi: 10.1158/1055-9965.EPI-10-0097
60.
PrewettM.C.HooperA.T.BassiR.EllisL.M.WaksalH.W.HicklinD.J., “Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibodyIMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts”, Clin. Cancer Res.8, 994 (2002).
61.
KopetzS.ChangG.J.OvermanM.J.EngC.SargentD.J.LarsonD.W.GrotheyA.VautheyJ.N.NagorneyD.M.McWilliamsR.R., “Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy”, J. Clin. Oncol.27, 36 (2009). doi: 10.1200/JCO.2008.20.5278
